Hospira, a Pfizer company, voluntarily recalled three lots of a blood pressure medication and two lots of a pain management therapy because of a potential packaging issue.
Three lots of buprenorphine hydrochloride, used for pain management, and two lots of labetalol hydrochloride, indicated for blood pressure control in severe hypertension cases, were recalled. The injectable drugs might have incomplete crimp seals, the FDA said May 21.
Pfizer has received one customer complaint about a leaking unit, and there are no reports of adverse events.
"Wholesalers and hospitals with an existing inventory of any of the lots which are being recalled should discontinue use, stop distribution and quarantine the product immediately," the FDA said.